Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Development and implementation of "Check of Medication Appropriateness" (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance.

Quintens C, De Rijdt T, Van Nieuwenhuyse T, Simoens S, Peetermans WE, Van den Bosch B, Casteels M, Spriet I.

BMC Med Inform Decis Mak. 2019 Feb 11;19(1):29. doi: 10.1186/s12911-019-0748-5.

2.

The necessity for a European definition of drug shortages.

De Weerdt E, Simoens S, Casteels M, Huys I.

Int J Pharm Pract. 2018 Aug;26(4):289-290. doi: 10.1111/ijpp.12459. No abstract available.

PMID:
29972611
3.

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.

Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé VO, Van Calster B, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2312-2318. doi: 10.1158/1078-0432.CCR-17-3028. Epub 2018 Feb 19.

4.

Time Investment in Drug Supply Problems by Flemish Community Pharmacies.

De Weerdt E, Simoens S, Casteels M, Huys I.

Front Pharmacol. 2017 Aug 23;8:568. doi: 10.3389/fphar.2017.00568. eCollection 2017.

5.

It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North-South collaborative trials.

Ravinetto R, Tinto H, Diro E, Okebe J, Mahendradhata Y, Rijal S, Gotuzzo E, Lutumba P, Nahum A, De Nys K, Casteels M, Boelaert M.

BMJ Glob Health. 2016 Nov 16;1(3):e000122. doi: 10.1136/bmjgh-2016-000122. eCollection 2016.

6.

Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population.

Hens B, Van Den Abeele J, Rubbens J, Keirsebilck M, Roelens J, Schreurs C, Verheyen K, Casteels M, Laekeman G, Augustijns P.

J Clin Pharm Ther. 2017 Aug;42(4):467-474. doi: 10.1111/jcpt.12535. Epub 2017 Apr 27.

PMID:
28452061
7.

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.

Pauwels K, Huys I, Vogler S, Casteels M, Simoens S.

Front Pharmacol. 2017 Apr 4;8:171. doi: 10.3389/fphar.2017.00171. eCollection 2017.

8.

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study.

De Weerdt E, De Rijdt T, Simoens S, Casteels M, Huys I.

PLoS One. 2017 Mar 28;12(3):e0174556. doi: 10.1371/journal.pone.0174556. eCollection 2017.

9.

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.

Pauwels K, Huys I, Casteels M, Larsson K, Voltz C, Penttila K, Morel T, Simoens S.

Orphanet J Rare Dis. 2017 Feb 16;12(1):36. doi: 10.1186/s13023-017-0578-4.

10.

Clinical, Economic and Policy Implications of Drug Shortages in the European Union.

De Weerdt E, Simoens S, Casteels M, Huys I.

Appl Health Econ Health Policy. 2017 Aug;15(4):441-445. doi: 10.1007/s40258-016-0264-z.

PMID:
27480539
11.

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs.

Pauwels K, Huys I, Casteels M, Simoens S.

Front Pharmacol. 2016 Jun 1;7:144. doi: 10.3389/fphar.2016.00144. eCollection 2016.

12.

Sponsorship in non-commercial clinical trials: definitions, challenges and the role of Good Clinical Practices guidelines.

Ravinetto R, De Nys K, Boelaert M, Diro E, Meintjes G, Adoke Y, Tagbor H, Casteels M.

BMC Int Health Hum Rights. 2015 Dec 30;15:34. doi: 10.1186/s12914-015-0073-8.

13.

Toward a European definition for a drug shortage: a qualitative study.

De Weerdt E, Simoens S, Casteels M, Huys I.

Front Pharmacol. 2015 Oct 30;6:253. doi: 10.3389/fphar.2015.00253. eCollection 2015.

14.

Qualitative Assessment of Societal Preferences for Market Access of Cancer Drugs.

Pauwels K, Huys I, Casteels M, Simoens S.

Value Health. 2015 Nov;18(7):A486. doi: 10.1016/j.jval.2015.09.1335. Epub 2015 Oct 20. No abstract available.

15.

Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.

Pauwels K, Huys I, De Nys K, Casteels M, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):859-68. doi: 10.1586/14737167.2015.1047347. Epub 2015 May 15.

PMID:
25978862
16.

Insights into European drug shortages: a survey of hospital pharmacists.

Pauwels K, Simoens S, Casteels M, Huys I.

PLoS One. 2015 Mar 16;10(3):e0119322. doi: 10.1371/journal.pone.0119322. eCollection 2015.

17.

Causes of drug shortages in the legal pharmaceutical framework.

De Weerdt E, Simoens S, Hombroeckx L, Casteels M, Huys I.

Regul Toxicol Pharmacol. 2015 Mar;71(2):251-8. doi: 10.1016/j.yrtph.2015.01.005. Epub 2015 Jan 12.

PMID:
25591547
18.

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?

Pauwels K, Huys I, Casteels M, Simoens S.

BMC Health Serv Res. 2014 Sep 26;14:438. doi: 10.1186/1472-6963-14-438.

19.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

20.

How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?

Dieudonné AS, De Nys K, Casteels M, Wildiers H, Neven P.

Acta Clin Belg. 2014 Jan-Feb;69(1):47-52. doi: 10.1179/0001551213Z.00000000017.

PMID:
24635399

Supplemental Content

Loading ...
Support Center